Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Receivables (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Receivables for 4 consecutive years, with $52000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables fell 54.78% to $52000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $52000.0, a 54.78% decrease, with the full-year FY2024 number at $92000.0, down 7.07% from a year prior.
  • Receivables was $52000.0 for Q3 2025 at Orchestra BioMed Holdings, down from $83000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $171000.0 in Q2 2023 to a low of $52000.0 in Q3 2025.
  • A 4-year average of $92166.7 and a median of $87500.0 in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 33.72% in 2024, then tumbled 54.78% in 2025.
  • Orchestra BioMed Holdings' Receivables stood at $96000.0 in 2022, then increased by 3.12% to $99000.0 in 2023, then dropped by 7.07% to $92000.0 in 2024, then plummeted by 43.48% to $52000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Receivables are $52000.0 (Q3 2025), $83000.0 (Q2 2025), and $89000.0 (Q1 2025).